Morton Grove Pharmaceuticals sold to ex-Fujisawa USA President Tambi.
Executive Summary
MORTON GROVE PHARMACEUTICALS SOLD TO FORMER FUJISAWA USA PRESIDENT TAMBI and Chicago-based William Blair Capital Partners. In a transaction announced Dec. 12, Brian Tambi acquired Morton Grove Pharmaceuticals, Inc. from JVL, Inc., a holding company formed by Jack Van Hulst and William Lyons. Tambi will serve as MGP's chairman, president and CEO. He previously was an exec at Lyphomed when it was acquired by Fujisawa. He was appointed Fujisawa USA president in 1990 and joined Ivax in 1992 as president of its North American pharmaceutical business.
You may also be interested in...
Wockhardt’s Illinois Drug Firm Closed In FDA Settlement After GMP Problems Found Since 2011
Permanent injunction states Morton Grove Pharmaceuticals intends to sell its facility. Complaint comes more than 10 years after first of five inspections found GMP problems.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials